INOVIO PHARMACEUTICALS, INC. Net Fee Amt
INOVIO PHARMACEUTICALS, INC. (INO) had Net Fee Amt of $36.32 thousand as of 2026-06-30, per its S-3 filed 2026-07-02.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-02
- 2026-06-30: Net Fee Amt $36.32K.
| Period end | Net Fee Amt |
|---|---|
| 2026-06-30 | $36.32K S-3 · filed 2026-07-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |